title: Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability.
abstract: Exon skipping uses antisense oligonucleotides (ASOs) to alter transcript splicing for the purpose of rescuing or modulating protein expression. In this issue of the JCI, Lee and colleagues developed and evaluated an ASO-dependent method for treating certain molecularly defined diseases associated with alterations in lamin A/C (LMNA) splicing. Exon skipping by ASOs is gaining traction as a therapeutic strategy, and the use of ASOs is now being applied to bypass mutations and generate modified but functional proteins for an array of genetic disorders.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: McNally
authors.forename: Eugene J
authors.initials: EJ
authors.lastname: Wyatt
mesh_terms: D017398:Alternative Splicing / Q000187:drug effects*; D000818:Animals; D006801:Humans; D034904:Lamin Type A / Q000096:biosynthesis*; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology*; D011371:Progeria / Q000188:drug therapy* / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism*
chemical_list: D034904:Lamin Type A; D020319:Oligodeoxyribonucleotides, Antisense; D012333:RNA, Messenger